267.   This is to present the second edition of the trilateral study promoting access to medical technologies and innovation – intersections between public health, intellectual property and trade. 268.   As you may know, the three organizations have been working closely together to support global endeavours to improve health outcomes, to strengthen the capacity of developing countries to respond to needs in the areas of health innovation, access to health, and intellectual property. The objective of the trilateral study is to provide an up-to-date platform for sharing practical experience and understanding of a wide range of policy instruments. We count on this document to support and inform the ongoing technical cooperation and policy discussions, in particular at a time when the world grapples with the multi-dimensional challenges of the response to the COVID-19 pandemic. 269.   The COVID-19 pandemic is a tragic and powerful demonstration of the importance of innovation and access for public health. Innovation is essential, but it is only part of the answer to this pandemic. Together, we must all ensure that vaccines, diagnostics and therapeutics for COVID19 are global public goods, not more reasons that more people are left behind. 270.   The trilateral study integrates lessons from diverse experiences regarding how public health, IP, trade and competition rules all interact with each other in the broader context of the human rights dimension of health and the united nations' sustainable development goals. We tried to include comprehensive and accessible data and information on prices, access, patents and licensing. 271.   The insert at the beginning of the study summarizes issues that have come up in the context of COVID-19, the pandemic has brought extraordinary challenges to peoples' health, economies and societies at large. Countries are also seeking at extraordinary solutions to respond. 272.   Global collaborative efforts are required now more than ever before to respond to challenging situations, not only for COVID-19 but also for other diseases, like HCV, cancer, HIV, etc. 273.   WHO pledges continuing commitment for further collaboration among our three agencies, together with other UN agencies, the private sector, funders, and civil society organizations, whose insights have contributed much to the study, only this will support our work towards the shared objectives of universal health coverage, better health outcomes for all, fulfilment of the Sustainable Development Goals (SDGs) and, first and foremost, the design of effective and lasting responses to public health crises.